Analyzing SI-Bone (NASDAQ:SIBN) and Invivo Therapeutics (NASDAQ:NVIV) – Riverton Roll

SI-Bone (NASDAQ:SIBN) and Invivo Therapeutics (NASDAQ:NVIV) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability and risk.

Earnings & Valuation

This table compares SI-Bone and Invivo Therapeutics revenue, earnings per share and valuation.

SI-Bone has higher revenue and earnings than Invivo Therapeutics. SI-Bone is trading at a lower price-to-earnings ratio than Invivo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares SI-Bone and Invivo Therapeutics net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings and price targets for SI-Bone and Invivo Therapeutics, as reported by MarketBeat.com.

SI-Bone currently has a consensus price target of $27.00, indicating a potential upside of 24.54%. Given SI-Bones higher possible upside, equities research analysts clearly believe SI-Bone is more favorable than Invivo Therapeutics.

Institutional and Insider Ownership

51.1% of SI-Bone shares are owned by institutional investors. Comparatively, 4.1% of Invivo Therapeutics shares are owned by institutional investors. 38.8% of SI-Bone shares are owned by company insiders. Comparatively, 1.5% of Invivo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Risk and Volatility

SI-Bone has a beta of -0.44, suggesting that its share price is 144% less volatile than the S&P 500. Comparatively, Invivo Therapeutics has a beta of 1.59, suggesting that its share price is 59% more volatile than the S&P 500.

Summary

SI-Bone beats Invivo Therapeutics on 9 of the 12 factors compared between the two stocks.

About SI-Bone

SI-BONE, Inc., a medical device company, develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. It offers iFuse, an implant system to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. The company was founded in 2008 and is headquartered in Santa Clara, California.

About Invivo Therapeutics

InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for implantation at the site of injury within a spinal cord. InVivo Therapeutics Holdings Corp. has research collaboration with the Q Therapeutics, Inc. for the evaluation of the combination of PLGA-PLL based Neuro-Spinal Scaffold with adult neural progenitor cells, including those from induced pluripotent stem cells. The company was founded in 2005 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings for SI-Bone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-Bone and related companies with MarketBeat.com's FREE daily email newsletter.

See more here:
Analyzing SI-Bone (NASDAQ:SIBN) and Invivo Therapeutics (NASDAQ:NVIV) - Riverton Roll